🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Inhibrx Biosciences, Inc. INBX R2K

Healthcare · Biotechnology · United States
https://inhibrx.com

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

READ MORE ›
$104.01
+672.16% 1Y

Market & Price

Market Cap
$1.53B
Current Price
$104.01
High / Low (52W)
$141.84 / $12.89
Beta
-

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$0.55
Price to Book
189.80
P/S
1,173.81
EV/EBITDA
-12.80
Dividend Yield
-

Profitability & Returns

ROCE
-113.47%
ROE
-
ROA
-36.06%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-2.15
EPS (TTM)
$-8.39

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
6.11
Current Ratio
6.46
Debt
$180.90M
Total Assets
$146.48M
Current Assets
$132.83M
Working Capital
$99.03M

Ownership

Promoter Holding
23.16%
Chg in Prom Hold
-
FII / Inst Holding
83.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$1.55B
Total Revenue (TTM)
$1.30M
EBITDA
$-120.71M
Free Cash Flow
$-89.11M
Operating Cash Flow
$-131.93M
Shares Outstanding
14.67M
Gross Margin
0.00%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
-0.03%
Profit 5Y
-7.15%
Revenue (YoY)
-
Earnings (YoY)
-

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -0.0% CAGR over 5 years.
  • Earnings shrank at -7.1% CAGR over 5 years.
  • Trading 26.7% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 INBX Inhibrx Biosciences, Inc. R2K 104.01 - $1.53B - -113.47% - -0.03% -7.15%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
⚙Ad space

Quarterly Results

Figures in USD.

Metric Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -30.00K119.00K0100.00K--01.30M000
Cost of Revenue ------------
Gross Profit ------------
Operating Expenses -------42.90M28.69M33.81M30.92M30.93M
Operating Income --41.34M-45.83M-73.83M-160.90M---42.90M-27.39M-33.81M-30.92M-30.93M
EBITDA --------39.95M-24.85M-31.49M-29.09M-29.39M
Interest Expense -------2.69M3.14M3.18M3.19M3.51M
Pretax Income --------43.31M-28.65M-35.26M-32.83M-33.44M
Tax Provision -------02.00K000
Net Income -48.92M-47.05M-51.79M-78.71M1.86B---43.31M-28.65M-35.26M-32.83M-33.44M
Diluted EPS --4.31-4.39-5.77125.48---2.80-1.85-2.28-2.11-2.15
R&D Expense -34.11M38.06M63.85M67.63M38.89M-36.88M22.27M28.54M-25.22M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 1.30M1.80M200.00K1.30M
Cost of Revenue ----
Gross Profit ----
Operating Expenses 116.62M221.02M331.65M136.32M
Operating Income -115.32M-219.22M-331.45M-135.03M
EBITDA -114.10M-206.69M1.70B-125.37M
Interest Expense -31.84M13.49M12.20M
Pretax Income -115.32M-239.72M1.69B-140.05M
Tax Provision 3.00K3.00K2.00K2.00K
Net Income -115.33M-241.36M1.69B-140.06M
Diluted EPS -8.10-16.95112.62-9.04
R&D Expense -191.64M203.74M113.03M

Compounded Sales Growth

5 Years:-0.03%
1 Year:-

Compounded Profit Growth

5 Years:-7.15%
1 Year:-

Stock Price Performance

1 Year:+672.16%
6 Months:+25.80%
3 Months:+40.31%
1 Month:-16.67%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets 16.64M307.89M180.77M146.48M
Current Assets 6.26M295.36M160.40M132.83M
Cash & Equivalents -277.92M152.60M124.22M
Inventory ----
Receivables 243.00K778.00K200.00K0
Total Liabilities 23.95M264.39M47.18M138.49M
Current Liabilities 20.77M56.31M40.73M33.80M
Long Term Debt -206.97M-100.56M
Total Debt 5.03M210.14M8.05M107.01M
Total Equity -7.30M43.50M133.58M7.99M
Shares Outstanding 14.24M14.24M14.48M14.58M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -90.81M-193.31M-194.41M-129.79M
Investing Cash Flow -686.00K-4.59M-2.60M-28.00K
Financing Cash Flow 91.50M201.96M71.68M101.45M
Capital Expenditure -686.00K-4.59M-2.60M-31.00K
Free Cash Flow -91.50M-197.90M-197.01M-129.82M
Net Change in Cash -4.06M-125.33M-28.38M

Ratios (Annual)

Figures in %.

Metric Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ----
Operating Margin % -8,864.2%-12,178.9%-165,724.0%-10,386.5%
Net Margin % -8,864.3%-13,408.9%843,786.0%-10,773.5%
ROE % 1,579.8%-554.8%1,263.3%-1,752.2%
ROCE % 2,794.4%-87.1%-236.7%-119.8%

Shareholding Pattern

Insiders
23.16%
Institutions
83.00%
Public Float
108.01%

Top Institutional Holders

#Holder% HeldSharesValue
1 Perceptive Advisors Llc 9.83% 1.44M $150.06M
2 Viking Global Investors, L.P. 9.80% 1.44M $149.54M
3 Morgan Stanley 8.61% 1.26M $131.37M
4 Sanofi 7.89% 1.16M $120.44M
5 HighTower Advisors, LLC 5.93% 870.20K $90.51M
6 Blackrock Inc. 5.45% 798.90K $83.09M
7 State Street Corporation 3.75% 550.85K $57.29M
8 Vanguard Capital Management LLC 3.32% 486.42K $50.59M
9 Sofinnova Investments, Inc. 2.77% 406.03K $42.23M
10 Capital Research Global Investors 2.68% 392.85K $40.86M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for INBX

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space